Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the 8 Most Promising Biotech Stocks to Buy Now.

On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares.

On May 7, Genmab A/S (NASDAQ:GMAB) reported revenue of $896 million for Q1 2026, rising 25% from $715 million a year earlier. The growth was because of higher DARZALEX and Kesimpta royalties and solid EPKINLY sales. Royalty income did the heavy lifting, soaring to $742 million from $589 million, as underlying drug sales expanded.

Costs climbed too, as Genmab A/S (NASDAQ:GMAB) reported operating expenses of $606 million, growing by 25%, showing pipeline growth and marketing investments. Profit held steady, posting an operating profit of $180 million compared to $188 million last year, while adjusted operating profit reached $237 million, up from $191 million.

Jan van de Winkel said Genmab A/S (NASDAQ:GMAB) made “tangible progress,” pushing late-stage programs and preparing for launches. It maintained 2026 guidance.

Genmab A/S (NASDAQ:GMAB) is a global biotechnology company that works on the development of human antibody therapies for cancer and other diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.